Bhavana Pothuri, MD

Articles

Dr Pothuri on Real-World Treatment Patterns Per MMR/MSI Status in Endometrial Cancer

June 27th 2024

Bhavana Pothuri, MD, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to MMR/MSI status.

Diversity and Access to Clinical Trials in Endometrial Cancer

December 4th 2023

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.

Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy

December 4th 2023

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.

Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status

November 27th 2023

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.

Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

November 27th 2023

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab

November 20th 2023

Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.

HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment

November 20th 2023

The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.

Treatment Choices for Recurrent dMMR Endometrial Cancer

November 13th 2023

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy

November 13th 2023

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.

Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors

November 6th 2023

Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.

Factors in Frontline Treatment Decision Making for Endometrial Cancer

November 6th 2023

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

Optimal Workup Strategies in Advanced Endometrial Cancer

October 30th 2023

Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.

Changing Landscape of Endometrial Cancer: Incidence and Classification

October 30th 2023

Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.

Dr Pothuri on the Use of ADCs in Ovarian Cancer

September 22nd 2023

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

Dr Pothuri on Treating Patients With Ovarian Cancer

September 19th 2023

Bhavana Pothuri, MD, discusses treatment considerations for patients in tough-to-treat subgroups of ovarian cancer based on currently available data.

Dr Pothuri on the Promise of the RUBY and NRG-GY018 Trials in Endometrial Cancer

September 7th 2023

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Dr Pothuri on the Phase 3 NRG-GY018 and RUBY Trials in Endometrial Cancer

August 25th 2023

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Future Outlook for Treatment of Endometrial Cancer

August 10th 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Ongoing Trials in Endometrial Cancer

August 10th 2023

An overview of ongoing research in the endometrial cancer treatment space.

KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

August 3rd 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.